Core Viewpoint - The announcement details the regulatory measures and penalties faced by Borui Biopharmaceuticals (Suzhou) Co., Ltd. over the past five years, emphasizing the company's commitment to compliance and governance improvements. Recent Regulatory Penalties - The company and its directors, supervisors, and senior management have not faced any penalties from regulatory authorities in the last five years [1] Recent Regulatory Measures and Rectification - On February 13, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the company's announcement on antiviral drug research progress, requiring clarification on the commercialization timeline and potential patent infringements related to the production of remdesivir [2] - The company responded that the remdesivir project is still in the preclinical research stage and that its production is limited to research purposes, thus not infringing on Gilead's patents [2][3] - On March 1, 2020, the Shanghai Stock Exchange issued a decision to place the company under regulatory scrutiny due to unclear information disclosure regarding the distinction between experimental production and commercial production [4] - The former board secretary was criticized for further confusing the terms during a media interview, leading to regulatory actions against him [5] - On March 11, 2020, the Jiangsu Securities Regulatory Bureau issued a warning letter, confirming that the company's disclosure of "batch production" was misleading and did not accurately reflect the drug development progress [7] - On June 30, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the establishment of an investment fund, requiring the company to enhance internal control mechanisms and ensure compliance in external investments [8] - On October 17, 2023, a warning letter was issued to an individual for misleading statements regarding a product still in clinical trials, emphasizing the need for accurate information disclosure [9] - On June 20, 2025, a warning letter was issued due to the company's failure to timely redeem idle fundraising cash management products, violating disclosure obligations [10][12] - The company has committed to improving compliance and internal management practices in response to these regulatory measures [11][14]